Overview

* Aethlon fiscal Q2 operating expenses drop 48% yr/yr, reflecting disciplined cost management

Outlook

* Company did not provide specific financial guidance for future quarters in its press release

* Co says clinical and research progress continues alongside substantial cost reductions

Result Drivers

* COST REDUCTIONS - Operating expenses decreased by 48% due to disciplined cost management, including lower headcount and reduced clinical trial costs

* REDUCED GENERAL AND ADMINISTRATIVE EXPENSES- Declined by approximately $437,000 driven by lower clinical trial costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $1.50

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Aethlon Medical Inc ( AEMD ) is $12.38, about 64.9% above its November 11 closing price of $4.34

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)